Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

IBUPROFENO RAPID STADAPHARM 400 MG CAPSULAS BLANDAS - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/IBUPROFENO RAPID STADAPHARM 400 MG CAPSULAS BLANDAS

Approved

STANDARD

IBUPROFENO RAPID STADAPHARM 400 MG CAPSULAS BLANDAS

Laboratorio Stada S.L.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Jun 16, 2022
Approval ID: 8d9b7eb3d6834e3f
Company: Laboratorio Stada S.L.
Type: Standard

Approval Details

Approval Id: 8d9b7eb3d6834e3f
Drug Cima Aemps Name: IBUPROFENO RAPID STADAPHARM 400 MG CAPSULAS BLANDAS
Register Number: 87837
Holder Company Name: Laboratorio Stada S.L.
Marketing Company Name: Laboratorio Stada S.L.
Authorization Date: 2022-06-16
Dosage Form: CÁPSULA BLANDA
Dose: 400 mg
Route Of Administration: VÍA ORAL
Prescription Type: Sin Receta
Commercialized: Yes
Company Name: Laboratorio Stada S.L.

Active Ingredients

IBUPROFENO

400 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Jun 16, 2022

Approval ID

8d9b7eb3d6834e3f

Type

Standard

Back to CIMA-AEMPS Approvals